Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "pharmaceutical-company"

723 News Found

FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Biotech | November 26, 2024

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR


CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance
Healthcare | November 26, 2024

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions


Emcure and MS Dhoni drive India’s fight against Anemia
Healthcare | November 21, 2024

Emcure and MS Dhoni drive India’s fight against Anemia

Emcure has launched an awareness campaign to help spread the word about male anemia


Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
News | November 16, 2024

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24


AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
News | November 14, 2024

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%


EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
Drug Approval | November 13, 2024

EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility

The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections


Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.


Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
News | November 06, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore